Gainor, Justin F.

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases

Mak, K. S., Gainor, J. F., Niemierko, A., Oh, K. S., Willers, H., Choi, N. C., Loeffler, J. S., Sequist, L. V., Shaw, A. T., & Shih, H. A. (2015) · Neuro-Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 83

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

Piotrowska, Z., Costa, D. B., Oxnard, G. R., Huberman, M., Gainor, J. F., Lennes, I. T., Muzikansky, A., Shaw, A. T., Azzoli, C. G., Heist, R. S., et al. (2018) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 79

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors

Riedl, J. M., Fece de la Cruz, F., Lin, J. J., Parseghian, C., Kim, J. E., Matsubara, H., Barnes, H., Caughey, B., Norden, B. L., Morales-Giron, A. A., et al. (2025) · Annals of Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 68

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

Bauman, J., Burris, H., Clarke, J., Patel, M., Cho, D., Gutierrez, M., Julian, R., Scott, A., Cohen, P., Frederick, J., et al. (2020) · Late-breaking abstracts

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 54

Developing biomarker-specific end points in lung cancer clinical trials

Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 51

Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center

Zubiri, L., Rosovsky, R. P., Mooradian, M. J., Piper-Vallillo, A. J., Gainor, J. F., Sullivan, R. J., Marte, D., Boland, G. M., Gao, X., Hochberg, E. P., et al. (2021) · The Oncologist

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 19

Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC

Cooper, A. J., Muzikansky, A., Lennerz, J., Narinesingh, F., Mino-Kenudson, M., Hung, Y. P., Piotrowska, Z., Dagogo-Jack, I., Sequist, L. V., Gainor, J. F., et al. (2022) · JTO Clinical and Research Reports

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 14